Indianapolis, Indiana – In response to the growing demand for weight-loss medications in the United States, pharmaceutical company Eli Lilly has announced plans to offer single-use vials of its popular drug Zepbound at a fraction of the cost of its pre-filled pens. This move comes as more Americans seek effective anti-obesity treatments amidst a rising trend in health-consciousness.
The decision to introduce the vials is part of Lilly’s strategy to compete with digital health companies that provide lower-cost compounded versions of medications in vials with syringes for injection. By offering these single-use vials, Eli Lilly aims to make its obesity medicine more accessible to a wider range of patients seeking safe and efficient treatment options.
According to Lilly’s president of Cardiometabolic Health and Lilly USA, Patrik Jonsson, the introduction of the vials not only addresses the high demand for the drug but also expands access to patients in need. The company will exclusively sell these vials through its telehealth platform, LillyDirect, catering to individuals whose insurance does not cover weight-loss medications and cannot afford the expensive pens.
The pricing of the Zepbound vials is set at $399 for a four-week supply of 2.5-milligram vials, and $549 for 5-milligram vials. This pricing is significantly lower compared to other similar medications on the market, making it a more affordable option for those with obesity. Jonsson emphasized the importance of innovative solutions in addressing the lack of coverage and outdated policies surrounding obesity medications.
By offering Zepbound in single-dose vials, Eli Lilly aims to help a larger population manage obesity as a chronic condition. The company also underscores the significance of advocating for a healthcare system that aligns better with scientific advancements and patient needs. This initiative reflects Lilly’s commitment to ensuring the authenticity and safety of its medications in the face of counterfeit products in the market.